Skip to main content
. 2004 Dec 14;92(1):131–139. doi: 10.1038/sj.bjc.6602258

Figure 1.

Figure 1

Meta-analysis of studies assessing RAS with IHC in NSCLC. Hazard ratio (HR) and 95% confidence interval (CI) of survival in studies evaluating RAS-p21 status in NSCLC. HR>1 implies a survival disadvantage for the group with p21 expression. The square size is proportional to the number of patients included in the study. The center of the lozenge gives the combined HR of the meta-analysis and its extremities the 95% confidence interval. HR=1.08; CI 95% 0.86–1.34. Total number of patients: 989.